ENTA · Enanta Pharmaceuticals, Inc.
The AI's read
Enanta's completed pediatric trial enrollment and adult trial start move its RSV program closer to results. But royalty revenue fell, interest costs rose, and Enanta pays OMERS 54.5% of these royalties through June 2032. Cash expected to fund operations into fiscal 2029 gives Enanta time, so the report points in different directions.